Background: Systematic treatment for advanced cancer offers uncertain and often limited benefits whilst the burden can be high. Hence, treatment decisions require Shared Decision Making (SDM). We examined the separate and combined effect of oncologist training and a patient communication aid on SDM in consultations about palliative systemic treatment. Methods: A multi-center RCT with four parallel arms was conducted (NTR 5489). To attain a power of 80%, we included 31 medical oncologists and 194 of their patients with advanced cancer with a median life expectancy of < 12 months. Oncologists were randomized to receive training or not; patients were randomized to receive a patient communication aid or not. The oncologist training consisted of a reader, two group sessions, a booster feedback session and a consultation room tool. The patient communication aid consisted of a question prompt list and a value clarification exercise. Either an initial consultation about the start of systemic treatment or an evaluative consultation about (dis)continuation was audio-recorded for each patient. The primary outcome was observed SDM (OPTION12), rated by blinded assessors. Intervention effects were investigated with multilevel analysis. 
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Methods:
The model was trained and tested using data from 12,588 patients treated for metastatic cancer in the Stanford Health Care system from 2008-2017. Data sources included provider note text, labs, vital signs, procedures, medication orders, and diagnosis codes. Patients were divided randomly into training and test sets (80%/20% split). A regularized Cox proportional hazards model with 4,126 predictor variables was fit to the training set and evaluated on the test set. A landmarking approach was used due to the multiple observations per patient, with t 0 set to the time of metastatic cancer diagnosis. Performance was also evaluated using 399 palliative radiation courses in test set patients. An existing published model that uses performance status, primary tumor site, and treated site was used as a baseline [Chow, JCO 2008:20; 26(36)] . Results: From the first visit after metastatic cancer diagnosis, median follow-up was 14.5 months and median overall survival was 20.9 months. Patients were seen for 384,402 daily visits. The prognostic model's C-index for overall survival was 0.79 in the test set (averaged across landmark times). For palliative radiation courses, the C-index was 0.75 (95% CI 0.72-0.78), compared to 0.64 (95% CI 0.60-0.67) for an existing published model (p < 0.001). Table: 1512O Predicted vs actual survival for 2,518 test set patients at landmark time t 0 (first visit after diagnosis of metastatic cancer)
Predicted median survival in months
Actual median survival in months (95% CI) 0-3 (n ¼ 106) 1.3 (0.9-2.0) 3.1-6 (n ¼ 172) 3.7 (2.5-5.2) 6.1-12 (n ¼ 382) 6.7 (5.6-7.9) >12 (n ¼ 1858)
35.7 (31.8-39.1)
Conclusions:
The model showed high predictive performance, which was significantly better than that of an existing model. Because it is fully automated, the model can be used to examine providers' practice patterns and could deployed in a decision support tool to help improve quality of care. Legal entity responsible for the study: Michael Gensheimer. Background: A predictive model of cachexia development would help identify those at greatest risk for early therapeutic intervention. The aims of this study were to identify predictors of cachexia development and to use these to create and evaluate the accuracy of a predictive model. Methods: A secondary analysis of an international, prospective, observational multicentre study was conducted. Patients with incurable cancer and without cachexia, who attended a palliative care unit were amenable to the analysis. Cachexia was defined as weight loss (WL) >5% (6 months) or WL > 2% and body mass index<20kg/m 2 . Disease related, demographic and patient reported markers were evaluated as possible 
